Literaturverzeichnis & Quellen

Hier finden Sie die wissenschaftlichen Fachartikel, die das Fundament unserer Arbeit sind. Alle Arbeiten sind in anerkannten wissenschaftlichen Journalen nach dem sogenannten Peer-review Verfahren veröffentlicht, entsprechen also dem höchsten wissenschaftlichen Standard. Fast alle dieser Arbeiten sind öffentlich zugänglich. Wollen Sie mehr erfahren, kopieren Sie die Literaturstelle in Ihren Browser und Sie finden die Originalarbeit.

1. Herrlinger U, Schafer N, Steinbach JP, et al. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol. May 10 2016;34(14):1611-9. doi:10.1200/JCO.2015.63.4691
2. Herrlinger U, Tzaridis T, Mack F, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. Feb 16 2019;393(10172):678-688. doi:10.1016/S0140-6736(18)31791-4
3. Schafer N, Proescholdt M, Steinbach JP, et al. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol. Jun 18 2018;20(7):975-985. doi:10.1093/neuonc/nox204
4. Tzaridis T, Schafer N, Weller J, et al. MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial. Int J Cancer. Apr 1 2021;148(7):1695-1707. doi:10.1002/ijc.33363
5. Weller M, Tabatabai G, Kastner B, et al. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clin Cancer Res. May 1 2015;21(9):2057-64. doi:10.1158/1078-0432.CCR-14-2737
6. Wick A, Kessler T, Platten M, et al. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. Neuro Oncol. Aug 17 2020;22(8):1162-1172. doi:10.1093/neuonc/noaa033
7. Zeyen T, Potthoff AL, Nemeth R, et al. Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial. Trials. Jan 19 2022;23(1):57. doi:10.1186/s13063-021-05977-0
8. Wick W, Roth P, Hartmann C, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. Nov 2016;18(11):1529-1537. doi:10.1093/neuonc/now133
9. Sabel M, Staub-Bartelt F, Todter J, et al. Improved Availability of Fluorescence-Guided Surgery of Malignant Brain Tumors: A Headlamp-Loupe System Combined With Generic 5-Aminolevulinic Acid Replaces the Microscope-A Monocentric Feasibility Study. World Neurosurg. Jun 2025;198:123967. doi:10.1016/j.wneu.2025.123967
10. Campian JL, Le SB, Ghiaseddin A, et al. Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial. Nat Commun. Feb 26 2026;17(1)doi:10.1038/s41467-026-69522-w
11. Latzer P, Zelba H, Battke F, et al. A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nat Commun. Aug 11 2024;15(1):6870. doi:10.1038/s41467-024-51315-8
12. Rapp M, Grauer OM, Kamp M, et al. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Trials. May 25 2018;19(1):293. doi:10.1186/s13063-018-2659-7
13. Liau LM, Ashkan K, Brem S, et al. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol. Jan 1 2023;9(1):112-121. doi:10.1001/jamaoncol.2022.5370
14. Galldiks N, Stoffels G, Filss C, et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol. Sep 2015;17(9):1293-300. doi:10.1093/neuonc/nov088
15. Satish S, Athavale M, Kharkar PS. Targeted therapies for Glioblastoma multiforme (GBM): State-of-the-art and future prospects. Drug Dev Res. Nov 2024;85(7):e22261. doi:10.1002/ddr.22261
16. Bonucci M, Fuggetta MP, Anelli L, Giannarelli D, Fiorentini C, Ravagnan G. New Approach for Enhancing Survival in Glioblastoma Patients: A Longitudinal Pilot Study on Integrative Oncology. Cancers (Basel). Jul 12 2025;17(14)doi:10.3390/cancers17142321
17. Duffau H. A series of 309 awake surgeries with transcortical approach for IDH-mutant low-grade glioma involving the insula: long-term onco-functional outcomes in 253 consecutive patients. J Neurosurg. Sep 1 2025;143(3):765-772. doi:10.3171/2025.1.JNS242462
18. Staub-Bartelt F, Rapp M, Sabel M. Feasibility of intraoperative neuromonitoring and cortical/subcortical mapping in patients with cerebral lesions of highly functional localizations-pathway to case adapted monitoring and mapping procedures. Front Oncol. 2023;13:1235212. doi:10.3389/fonc.2023.1235212
19. Staub-Bartelt F, Rapp M, Sabel M. Resection of Eloquent Located Brain Tumors by Mapping Only-A Feasibility Study. Brain Sci. Sep 25 2023;13(10)doi:10.3390/brainsci13101366
20. Staub-Bartelt F, Suresh Babu MP, Szelenyi A, Rapp M, Sabel M. Establishment of Different Intraoperative Monitoring and Mapping Techniques and Their Impact on Survival, Extent of Resection, and Clinical Outcome in Patients with High-Grade Gliomas-A Series of 631 Patients in 14 Years. Cancers (Basel). Feb 25 2024;16(5)doi:10.3390/cancers16050926
21. Sabel M, Staub-Bartelt F, Todter J, et al. In Reply to the Letter to the Editor Regarding „Improved Availability of Fluorescence-Guided Surgery of Malignant Brain Tumors: A Headlamp-Loupe System Combined With Generic 5-Aminolevulinic Acid Replaces the Microscope-A Monocentric Feasibility Study“. World Neurosurg. Dec 2025;204:124571. doi:10.1016/j.wneu.2025.124571
22. Jansen NL, Graute V, Armbruster L, et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging. Jun 2012;39(6):1021-9. doi:10.1007/s00259-012-2109-9
23. Jansen NL, Suchorska B, Wenter V, et al. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med. Feb 2014;55(2):198-203. doi:10.2967/jnumed.113.122333
24. Langen KJ, Stoffels G, Filss CP, et al. Borderline Findings in O-(2-[(18)F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice. J Nucl Med. Feb 3 2025;66(2):187-193. doi:10.2967/jnumed.124.268768
25. Rapp M, Ozcan Z, Steiger HJ, Wernet P, Sabel MC, Sorg RV. Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J Neurosurg. Jul 2006;105(1):41-50. doi:10.3171/jns.2006.105.1.41
26. Staub-Bartelt F, Hofmann BB, Rapp M, Hanggi D, Kamp MA, Sabel M. Direct Cortical Stimulation in Neurosurgical Emergencies: Single-Center Experience in 2 Patients. World Neurosurg. Jun 2021;150:147-152. doi:10.1016/j.wneu.2021.03.118
27. Staub-Bartelt F, Obermayr S, Sabel M, Rapp M. Influence of neuropathological diagnosis on psychooncological distress in neurooncological patients – a retrospective cross-sectional analysis. Front Oncol. 2024;14:1457017. doi:10.3389/fonc.2024.1457017
28. Staub-Bartelt F, Steinmann J, Radtke O, Hanggi D, Sabel M, Rapp M. Impact of COVID-19 Epidemic on Psycho-Oncological Distress in Neuro-Oncological Patients. Curr Oncol. Dec 26 2022;30(1):358-369. doi:10.3390/curroncol30010029
29. Staub-Bartelt F, Steinmann J, Wienand M, Sabel M, Rapp M. Increased Distress in Neurooncological Patients, a Monocentric Longitudinal Study: When to Screen Which Patient? Diseases. Sep 16 2024;12(9)doi:10.3390/diseases12090217
30. Kamp MA, Santacroce A, Zella S, et al. Is it a glioblastoma? In dubio pro 5-ALA! Acta Neurochir (Wien). Jul 2012;154(7):1269-73. doi:10.1007/s00701-012-1369-2
31. Heinzel A, Dedic D, Galldiks N, et al. Two Decades of Brain Tumour Imaging with O-(2-[(18)F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Julich Experience. Cancers (Basel). Jul 8 2022;14(14)doi:10.3390/cancers14143336
32. Larsen VA, Simonsen HJ, Law I, Larsson HB, Hansen AE. Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis. Neuroradiology. Feb 2013;55(3):361-9. doi:10.1007/s00234-012-1127-4
33. Lee DY, Oh JS, Kim JW, et al. Pre-operative dual-time-point [(18)F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study. Eur J Nucl Med Mol Imaging. Jan 2025;52(2):669-682. doi:10.1007/s00259-024-06935-z
34. Mauler J, Lohmann P, Maudsley AA, et al. Diagnostic Accuracy of MR Spectroscopic Imaging and (18)F-FET PET for Identifying Glioma: A Biopsy-Controlled Hybrid PET/MRI Study. J Nucl Med. Jan 2 2024;65(1):16-21. doi:10.2967/jnumed.123.265868
35. Muller M, Winz O, Gutsche R, et al. Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression. J Neurooncol. Sep 2022;159(3):519-529. doi:10.1007/s11060-022-04089-2
36. Chandar JS, Bhatia S, Ingle S, et al. Laser Interstitial Thermal Therapy Induces Robust Local Immune Response for Newly Diagnosed Glioblastoma With Long-term Survival and Disease Control. J Immunother. Nov-Dec 01 2023;46(9):351-354. doi:10.1097/CJI.0000000000000485
37. Rangwala HS, Shafique MA, Mustafa MS, et al. Evaluating efficacy and safety of laser interstitial thermal therapy in patients with newly diagnosed and recurrent glioblastoma: a systematic review and meta-analysis. Neurosurg Rev. Nov 12 2024;47(1):846. doi:10.1007/s10143-024-03077-6
38. Van Gool SW, Makalowski J, Kampers LFC, et al. Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached? Transl Cancer Res. Aug 31 2023;12(8):2224-2228. doi:10.21037/tcr-23-603
39. de Vleeschouwer S, Rapp M, Sorg RV, et al. Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery. Nov 2006;59(5):988-99; discussioin 999-1000. doi:10.1227/01.NEU.0000245595.38957.3E
40. Derks S, van der Veldt AAM, Smits M. Brain metastases: the role of clinical imaging. Br J Radiol. Feb 1 2022;95(1130):20210944. doi:10.1259/bjr.20210944
41. Singnurkar A, Poon R, Detsky J. 18F-FET-PET imaging in high-grade gliomas and brain metastases: a systematic review and meta-analysis. J Neurooncol. Jan 2023;161(1):1-12. doi:10.1007/s11060-022-04201-6
42. Patel L, Kolundzic N, Abedalthagafi M. Progress in personalized immunotherapy for patients with brain metastasis. NPJ Precis Oncol. Jan 29 2025;9(1):31. doi:10.1038/s41698-025-00812-0
43. Kamp MA, Dibue M, Santacroce A, et al. The tumour is not enough or is it? Problems and new concepts in the surgery of cerebral metastases. Ecancermedicalscience. 2013;7:306. doi:10.3332/ecancer.2013.306
44. Kamp MA, Grosser P, Felsberg J, et al. 5-aminolevulinic acid (5-ALA)-induced fluorescence in intracerebral metastases: a retrospective study. Acta Neurochir (Wien). Feb 2012;154(2):223-8; discussion 228. doi:10.1007/s00701-011-1200-5
45. Kamp MA, Slotty PJ, Cornelius JF, Steiger HJ, Rapp M, Sabel M. The impact of cerebral metastases growth pattern on neurosurgical treatment. Neurosurg Rev. Jan 2018;41(1):77-86. doi:10.1007/s10143-016-0760-5
46. Almeida T, Reyes JS, Scanlon SE, Frederico SC, Huq S, Hadjipanayis CG. Laser interstitial thermal therapy for recurrent brain metastases following stereotactic radiosurgery: a systematic review. Expert Rev Neurother. Apr 2025;25(4):465-475. doi:10.1080/14737175.2025.2471551
47. Cuschieri A, Borg M, Levinskaia E, Zammit C. LITT for biopsy proven radiation necrosis: A qualitative systematic review. J Clin Neurosci. Oct 2023;116:69-78. doi:10.1016/j.jocn.2023.08.020
48. Palmisciano P, Haider AS, Nwagwu CD, et al. Bevacizumab vs laser interstitial thermal therapy in cerebral radiation necrosis from brain metastases: a systematic review and meta-analysis. J Neurooncol. Aug 2021;154(1):13-23. doi:10.1007/s11060-021-03802-x
49. Garsa A, Jang JK, Baxi S, et al. Radiation Therapy for Brain Metastases: A Systematic Review. Pract Radiat Oncol. Sep-Oct 2021;11(5):354-365. doi:10.1016/j.prro.2021.04.002
50. Rapp M, Fischer H, Steinmann J, Sabel M, Staub-Bartelt F. Evaluation of Clinical Outcome and Survival Under Application of Various Therapies at First Recurrence in Patients with Glioblastoma. J Clin Med. Sep 17 2025;14(18)doi:10.3390/jcm14186550
51. Lavalle L, D’Elia A, Ciavarro M, Esposito V. Subpial technique in supratentorial glioma resection: state of the art and analysis of costs and effectiveness in a single institute experience. J Neurosurg Sci. Feb 2023;67(1):73-82. doi:10.23736/S0390-5616.20.05046-8
52. Ahluwalia M, Barnett GH, Deng D, et al. Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. J Neurosurg. Mar 1 2019;130(3):804-811. doi:10.3171/2017.11.JNS171273
53. Hernandez RN, Carminucci A, Patel P, Hargreaves EL, Danish SF. Magnetic Resonance-Guided Laser-Induced Thermal Therapy for the Treatment of Progressive Enhancing Inflammatory Reactions Following Stereotactic Radiosurgery, or PEIRs, for Metastatic Brain Disease. Neurosurgery. Jul 1 2019;85(1):84-90. doi:10.1093/neuros/nyy220
54. Hong CS, Deng D, Vera A, Chiang VL. Laser-interstitial thermal therapy compared to craniotomy for treatment of radiation necrosis or recurrent tumor in brain metastases failing radiosurgery. J Neurooncol. Apr 2019;142(2):309-317. doi:10.1007/s11060-019-03097-z
55. Kim AH, Tatter S, Rao G, et al. Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. Neurosurgery. Sep 1 2020;87(3):E338-E346. doi:10.1093/neuros/nyaa071
56. Mohammadi AM, Sharma M, Beaumont TL, et al. Upfront Magnetic Resonance Imaging-Guided Stereotactic Laser-Ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched Cohort of Biopsy-Only Patients. Neurosurgery. Dec 1 2019;85(6):762-772. doi:10.1093/neuros/nyy449
57. Munoz-Casabella A, Alvi MA, Rahman M, Burns TC, Brown DA. Laser Interstitial Thermal Therapy for Recurrent Glioblastoma: Pooled Analyses of Available Literature. World Neurosurg. Sep 2021;153:91-97 e1. doi:10.1016/j.wneu.2021.05.114
58. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. Jul 2011;115(1):3-8. doi:10.3171/2011.2.jns10998
59. Viozzi I, Guberinic A, Overduin CG, Rovers MM, Ter Laan M. Laser Interstitial Thermal Therapy in Patients with Newly Diagnosed Glioblastoma: A Systematic Review. J Clin Med. Jan 19 2021;10(2)doi:10.3390/jcm10020355
60. Yu JS, Meade SM, Zhao R, et al. Expedited chemoradiation after laser interstitial thermal therapy (LITT) is feasible and safe in patients with newly diagnosed glioblastoma. Neurooncol Adv. Jan-Dec 2025;7(1):vdaf038. doi:10.1093/noajnl/vdaf038
61. Kadali KR, Nierobisch N, Maibach F, et al. An effective MRI perfusion threshold based workflow to triage additional (18)F-FET PET in posttreatment high grade glioma. Sci Rep. Mar 5 2025;15(1):7749. doi:10.1038/s41598-025-90472-8
62. Prager AJ, Martinez N, Beal K, Omuro A, Zhang Z, Young RJ. Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol. May 2015;36(5):877-85. doi:10.3174/ajnr.A4218
63. Thomas AA, Arevalo-Perez J, Kaley T, et al. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. J Neurooncol. Oct 2015;125(1):183-90. doi:10.1007/s11060-015-1893-z
64. Galijasevic M, Steiger R, Mangesius S, et al. Magnetic Resonance Spectroscopy in Diagnosis and Follow-Up of Gliomas: State-of-the-Art. Cancers (Basel). Jun 29 2022;14(13)doi:10.3390/cancers14133197
65. Everard A, Versnel D, Ruijters V, et al. Comparison of (18)F-FET-PET- and MRI-based target definition for re-irradiation treatment of recurrent diffuse glioma. Clin Transl Radiat Oncol. May 2025;52:100931. doi:10.1016/j.ctro.2025.100931
66. Harat M, Miechowicz I, Rakowska J, Zarebska I, Malkowski B. A Biopsy-Controlled Prospective Study of Contrast-Enhancing Diffuse Glioma Infiltration Based on FET-PET and FLAIR. Cancers (Basel). Mar 24 2024;16(7)doi:10.3390/cancers16071265
67. Robert JA, Leclerc A, Ducloie M, Emery E, Agostini D, Vigne J. Contribution of [(18)F]FET PET in the Management of Gliomas, from Diagnosis to Follow-Up: A Review. Pharmaceuticals (Basel). Sep 18 2024;17(9)doi:10.3390/ph17091228
68. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. Nov 2014;14(11):754-62. doi:10.1038/nrc3829
69. Yeom E, Yu K. Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia. Exp Mol Med. Apr 2022;54(4):426-432. doi:10.1038/s12276-022-00752-w
70. Braun TP, Marks DL. The regulation of muscle mass by endogenous glucocorticoids. Front Physiol. 2015;6:12. doi:10.3389/fphys.2015.00012
71. Wang W, Zhao R, Liu B, Li K. The effect of curcumin supplementation on cognitive function: an updated systematic review and meta-analysis. Front Nutr. 2025;12:1549509. doi:10.3389/fnut.2025.1549509
72. Montecillo-Aguado M, Tirado-Rodriguez B, Tong Z, et al. Importance of the Role of omega-3 and omega-6 Polyunsaturated Fatty Acids in the Progression of Brain Cancer. Brain Sci. Jun 17 2020;10(6)doi:10.3390/brainsci10060381
73. Shen CC, Yang MY, Hsieh WY, et al. Berberine’s Impact on Apoptosis, Proliferation, Uptake Efficiency, and Nanoparticle-Based Therapy in DBTRG Cells. ACS Nanosci Au. Jun 18 2025;5(3):165-183. doi:10.1021/acsnanoscienceau.5c00004
74. Mundi MS, Mohamed Elfadil O, Patel I, Patel J, Hurt RT. Ketogenic diet and cancer: Fad or fabulous? JPEN J Parenter Enteral Nutr. Nov 2021;45(S2):26-32. doi:10.1002/jpen.2226
75. Barrea L, Caprio M, Tuccinardi D, et al. Could ketogenic diet „starve“ cancer? Emerging evidence. Crit Rev Food Sci Nutr. 2022;62(7):1800-1821. doi:10.1080/10408398.2020.1847030
76. Schreck KC, Hsu FC, Berrington A, et al. Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma. Neurology. Aug 31 2021;97(9):e953-e963. doi:10.1212/WNL.0000000000012386
77. Bettariga F, Galvao DA, Taaffe DR, et al. Association of muscle strength and cardiorespiratory fitness with all-cause and cancer-specific mortality in patients diagnosed with cancer: a systematic review with meta-analysis. Br J Sports Med. May 2 2025;59(10):722-732. doi:10.1136/bjsports-2024-108671
78. Furtner J, Berghoff AS, Albtoush OM, et al. Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. Eur Radiol. Aug 2017;27(8):3167-3173. doi:10.1007/s00330-016-4707-6
79. Sandler CX, Gildea GC, Spence RR, et al. The safety, feasibility, and efficacy of an 18-week exercise intervention for adults with primary brain cancer – the BRACE study. Disabil Rehabil. Jun 2024;46(11):2317-2326. doi:10.1080/09638288.2023.2221041
80. Rottgering JG, Douw L, de Witt Hamer PC, et al. Reducing severe fatigue in patients with diffuse glioma: a study protocol for an RCT on the effect of blended cognitive behavioural therapy. Trials. Jul 15 2022;23(1):568. doi:10.1186/s13063-022-06485-5
81. Andersen BL, Lacchetti C, Ashing K, et al. Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update. J Clin Oncol. Jun 20 2023;41(18):3426-3453. doi:10.1200/JCO.23.00293
82. Stanerova E, Zelenayova V, Rajcani J. Mindfulness-based interventions for cancer patients in standard treatment: A meta-analysis of effects on depression, anxiety, and quality of life. J Psychosom Res. Sep 2025;196:112312. doi:10.1016/j.jpsychores.2025.112312
83. Telles R, Whitney BM, Froelich S, Lutgendorf SK. Mindfulness-based psychosocial interventions and psychological wellbeing in cancer survivorship: a meta-analysis. Health Psychol Rev. Dec 2024;18(4):723-749. doi:10.1080/17437199.2024.2336014
84. Boele FW, Weimer JM, Marsland AL, et al. Correction to: The effects of SmartCare(c) on neuro‑oncology family caregivers‘ distress: a randomized controlled trial. Support Care Cancer. Aug 2022;30(8):7041. doi:10.1007/s00520-022-07146-8
85. Boele FW, Weimer JM, Marsland AL, et al. The effects of SmartCare((c)) on neuro-oncology family caregivers‘ distress: a randomized controlled trial. Support Care Cancer. Mar 2022;30(3):2059-2068. doi:10.1007/s00520-021-06555-5
86. Forst DA, Kaslow-Zieve ER, Hansen A, et al. Characterizing Distress and Identifying Modifiable Intervention Targets for Family Caregivers of Patients with Malignant Gliomas. J Palliat Med. Jan 2023;26(1):17-27. doi:10.1089/jpm.2021.0534
87. Evans M, McDonald AC, Xiong L, Crowley DC, Guthrie N. A Randomized, Triple-Blind, Placebo-Controlled, Crossover Study to Investigate the Efficacy of a Single Dose of AlphaWave((R)) L-Theanine on Stress in a Healthy Adult Population. Neurol Ther. Dec 2021;10(2):1061-1078. doi:10.1007/s40120-021-00284-x
88. Dasdelen MF, Er S, Kaplan B, et al. A Novel Theanine Complex, Mg-L-Theanine Improves Sleep Quality via Regulating Brain Electrochemical Activity. Front Nutr. 2022;9:874254. doi:10.3389/fnut.2022.874254
89. Marcos-Frutos D, Leban Z, Li Z, et al. The Impact of Rhodiola Rosea Extract on Strength Performance in Alternative Bench-Press and Bench-Pull Exercises Under Resting and Mental Fatigue Conditions: A Randomized, Triple-Blinded, Placebo-Controlled, Crossover Trial. Nutrients. Mar 7 2025;17(6)doi:10.3390/nu17060940
90. Ivanova Stojcheva E, Quintela JC. The Effectiveness of Rhodiola rosea L. Preparations in Alleviating Various Aspects of Life-Stress Symptoms and Stress-Induced Conditions-Encouraging Clinical Evidence. Molecules. Jun 17 2022;27(12)doi:10.3390/molecules27123902
91. Varga P, Lehoczki A, Fekete M, et al. The Role of Magnesium in Depression, Migraine, Alzheimer’s Disease, and Cognitive Health: A Comprehensive Review. Nutrients. Jul 4 2025;17(13)doi:10.3390/nu17132216
92. Wang W, Ou Z, Huang X, et al. Microbiota and glioma: a new perspective from association to clinical translation. Gut Microbes. Jan-Dec 2024;16(1):2394166. doi:10.1080/19490976.2024.2394166
93. Mehelleb D, Ghidouche A, Baldi S, et al. Specific Intratumoral Microbiome Signatures in Human Glioblastoma and Meningioma: Evidence for a Gut-Brain Microbial Axis. Int J Mol Sci. Nov 22 2025;26(23)doi:10.3390/ijms262311290
94. Montella L, Sarno F, Altucci L, et al. A Root in Synapsis and the Other One in the Gut Microbiome-Brain Axis: Are the Two Poles of Ketogenic Diet Enough to Challenge Glioblastoma? Front Nutr. 2021;8:703392. doi:10.3389/fnut.2021.703392